Policy & Regulation
Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology annual meeting
15 May 2019 - - US-based biotechnology company Magenta Therapeutics (NASDAQ: MGTA) presented Phase 2 clinical data on its cell therapy, MGTA-456, at the annual meeting of the American Academy of Neurology in Philadelphia, Pennsylvania, the company said.

MGTA-456 is a cell therapy designed to provide a high dose of hematopoietic stem cells that are well-matched to the patient.

The company plans to enroll 12 patients in the ongoing Phase 2 study in inherited metabolic disorders, which include cALD, Hurler syndrome, metachromatic leukodystrophy and globoid cell leukodystrophy.

The primary endpoint of the study is neutrophil engraftment after transplantation. The study is also collecting both short- and long-term disease-specific outcomes.

Data from the first five evaluable patients treated in this study were highlighted in a poster presented by Ashish Gupta, MBBS, M.P.H., Assistant Professor, Department of Pediatrics and Division of Blood and Marrow Transplantation, University of Minnesota.

In a separate oral presentation TODAY, Kevin Goncalves, Ph.D., Magenta Therapeutics, will highlight preclinical data demonstrating that the high stem cell dose in MGTA-456 accelerates and improves engraftment of human microglia in the brains of transplanted mice.

Patients with Inherited Metabolic Disorders transplanted with MGTA-456, a CD34+ Expanded Cell Therapy Product, Show Rapid Engraftment in Preliminary Phase 2 Trial Results.

Both patients had stable neurological function scores, which remained unchanged between baseline and six months post-transplant, suggesting progress of the disease has been arrested.

The Loes score, a method for quantifying the severity of brain abnormalities and atrophy found on MRI, also remained stable in both patients after six months.

Both patients showed resolution of gadolinium enhancement on MRI, an indicator of brain inflammation, by one month post-transplant, and the resolution persisted at six months.

Durable resolution of gadolinium enhancement is correlated with long-term disease benefit in patients with cALD.

As previously reported, all three patients with Hurler syndrome achieved normal levels of blood leukocyte IDUA enzyme, the enzyme that is deficient in untreated patients with Hurler syndrome, by Day 42 post-transplant.

This suggests that transplant with MGTA-456 is affecting the disease process in these patients.

Normalisation of blood leukocyte IDUA enzyme after transplant has been significantly associated with improvement in disease.

Patients showed a marked decline in urine total glycosaminoglycan, the toxic metabolites implicated in disease, after transplant.

Both of these findings are correlated with improved long-term disease outcomes, the company said.


Related Headlines